NCT03176381 is a clinical trial in Metastatic Castration-resistant Prostate Cancer, sponsored by Tianjin Medical University Second Hospital.

Who is sponsoring NCT03176381?

NCT03176381 is sponsored by Tianjin Medical University Second Hospital.

What condition does NCT03176381 study?

NCT03176381 studies Metastatic Castration-resistant Prostate Cancer.

Is NCT03176381 still recruiting?

NCT03176381 is currently completed. Last updated 14 November 2023.

Last reviewed 2023-11-14 · How we verify

NCT03176381

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tissue Predictors of Abiraterone Benefit

Completed Last updated 14 November 2023

What this trial tests

trial in Metastatic Castration-resistant Prostate Cancer in 110 participants. Completed in 1 November 2023.

Timeline

5 May 2017

Primary endpoint
1 May 2023

1 November 2023

Quick facts

Lead sponsor	Tianjin Medical University Second Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	110
Start date	5 May 2017
Primary completion	1 May 2023
Estimated completion	1 November 2023
Sites	1 location across China

Conditions studied

Metastatic Castration-resistant Prostate Cancer — all drugs for Metastatic Castration-resistant Prostate Cancer →

Sponsor

Tianjin Medical University Second Hospital

Who can join

18 and older, male only, with Metastatic Castration-resistant Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an observational, prospective (study following participants forward in time), multi-center (study conducted in more than 1 center) study to identify the predictive factors that will effectively predict the response to abiraterone treatment in metastatic castration-resistant prostate cancer (mCRPC). The entire duration of study will be approximately 3 year. Participants will primarily be evaluated for achieving biochemical or radiological progression after receiving abiraterone treatment based on EAU 2017 practice guideline criteria. For this, we put our attentions on the HOXB3 (an alternative factor of WNT signaling pathway), FKBP5 (FK506 Binding Protein 5, Androgen-regulated gene), NTS (neurotensin, neuroendocrine differentiation can be induced by NTS) and YAP1 (yes-associated protein 1, a biomarker for cancer stem cell), which are selected from the data of gene-array for various subtypes of CRPC (unpublished data). Response to abiraterone treatment will also be predicted using other androgen-regulated genes like AKR1C3 and PCNA.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Wnt signaling in cancer: from biomarkers to targeted therapies and clinical translation.
Tufail M, Jiang CH, Li N. · · 2025 · cited 36× · PMID 40170063 · DOI 10.1186/s12943-025-02306-w
HOXB3 drives WNT-activation associated progression in castration-resistant prostate cancer.
Zhu S, Yang Z, Zhang Z, Zhang H, et al · · 2023 · cited 6× · PMID 36973255 · DOI 10.1038/s41419-023-05742-y

Verify or expand the search:

Other recruiting trials for Metastatic Castration-resistant Prostate Cancer

Currently open trials in the same condition.

NCT07142551 — Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response · Phase 2 · recruiting
NCT07288359 — Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and · Phase 1, PHASE2 · recruiting
NCT07244341 — A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer ( · Phase 1 · recruiting
NCT07213674 — A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic · Phase 3 · recruiting
NCT07189403 — A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resist · Phase 1 · recruiting

Other Tianjin Medical University Second Hospital trials

Trials by the same sponsor.

NCT07170293 — Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors · Phase 2 · recruiting
NCT07475403 — Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer · Phase 2 · recruiting
NCT07321197 — Radical Nephrectomy With vs Without Template Lymph Node Dissection in High-Risk Renal Cell Carcinoma (T-LND RCC): A Rand · NA · not yet recruiting
NCT07321210 — Radical Nephroureterectomy With vs Without Template Lymph Node Dissection in High-Risk Upper Tract Urothelial Carcinoma · NA · recruiting
NCT07233252 — Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03176381 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tianjin Medical University Second Hospital
Last refreshed: 14 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03176381.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing